J u m p t o c o n t e n t
M a i n m e n u
M a i n m e n u
N a v i g a t i o n
● M a i n p a g e ● C o n t e n t s ● C u r r e n t e v e n t s ● R a n d o m a r t i c l e ● A b o u t W i k i p e d i a ● C o n t a c t u s ● D o n a t e
C o n t r i b u t e
● H e l p ● L e a r n t o e d i t ● C o m m u n i t y p o r t a l ● R e c e n t c h a n g e s ● U p l o a d f i l e
S e a r c h
Search
A p p e a r a n c e
● C r e a t e a c c o u n t ● L o g i n
P e r s o n a l t o o l s
● C r e a t e a c c o u n t ● L o g i n
P a g e s f o r l o g g e d o u t e d i t o r s l e a r n m o r e ● C o n t r i b u t i o n s ● T a l k
( T o p )
1 M e d i c a l u s e s
2 S i d e e f f e c t s
3 I n t e r a c t i o n s
4 C h e m i s t r y
5 H i s t o r y
6 S o c i e t y a n d c u l t u r e
T o g g l e S o c i e t y a n d c u l t u r e s u b s e c t i o n
6 . 1 P a t e n t s
6 . 2 A v a i l a b i l i t y
7 R e s e a r c h
8 R e f e r e n c e s
T o g g l e t h e t a b l e o f c o n t e n t s
L a n s o p r a z o l e
3 0 l a n g u a g e s
● ا ل ع ر ب ي ة ● ت ۆ ر ک ج ه ● ব া ং ল া ● C y m r a e g ● D e u t s c h ● Ε λ λ η ν ι κ ά ● E s p a ñ o l ● ف ا ر س ی ● F r a n ç a i s ● H r v a t s k i ● B a h a s a I n d o n e s i a ● I t a l i a n o ● ע ב ר י ת ● M a g y a r ● N e d e r l a n d s ● 日 本 語 ● ଓ ଡ ଼ ି ଆ ● P o l s k i ● P o r t u g u ê s ● R o m â n ă ● Р у с с к и й ● S l o v e n š č i n a ● С р п с к и / s r p s k i ● S r p s k o h r v a t s k i / с р п с к о х р в а т с к и ● S u o m i ● S v e n s k a ● T ü r k ç e ● У к р а ї н с ь к а ● T i ế n g V i ệ t ● 中 文
E d i t l i n k s
● A r t i c l e ● T a l k
E n g l i s h
● R e a d ● E d i t ● V i e w h i s t o r y
T o o l s
T o o l s
A c t i o n s
● R e a d ● E d i t ● V i e w h i s t o r y
G e n e r a l
● W h a t l i n k s h e r e ● R e l a t e d c h a n g e s ● U p l o a d f i l e ● S p e c i a l p a g e s ● P e r m a n e n t l i n k ● P a g e i n f o r m a t i o n ● C i t e t h i s p a g e ● G e t s h o r t e n e d U R L ● D o w n l o a d Q R c o d e ● W i k i d a t a i t e m
P r i n t / e x p o r t
● D o w n l o a d a s P D F ● P r i n t a b l e v e r s i o n
I n o t h e r p r o j e c t s
● W i k i m e d i a C o m m o n s
A p p e a r a n c e
F r o m W i k i p e d i a , t h e f r e e e n c y c l o p e d i a
Stomach acid suppressing medication
Lansoprazole Pronunciation lan-SOH -prə-zohl Trade names Prevacid, others Other names AG 1749 AHFS /Drugs.com Monograph MedlinePlus a695020 License data
Pregnancy
Routes of By mouth , intravenous Drug class Proton pump inhibitor ATC code Legal status
UK POM (Prescription only)
US WARNING [2] Rx-only[3]
Bioavailability 80% or more Protein binding 97% Metabolism Liver (CYP3A4 - and CYP2C19 -mediated)Elimination half-life 1.0–1.5 hours Excretion Kidney and fecal
(RS H d ]imidazole
CAS Number PubChem CID IUPHAR/BPS DrugBank ChemSpider UNII KEGG ChEBI ChEMBL CompTox Dashboard (EPA ) ECHA InfoCard 100.173.220 Formula C 16 H 14 F 3 N 3 O 2 S Molar mass −1 3D model (JSmol ) Chirality Racemic mixture Melting point 178 °C (352 °F) (decomposes)
FC(F )(F )COc1ccnc(c1C)CS(=O)c2[nH ]c3ccccc3n2
InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10 )24-9-16(17,18)19)8-25(23 )15-21-11-4-2-3-5-12(11 )22-15/h2-7H,8-9H2,1H3,(H,21,22) Y
Key:MJIHNNLFOKEZEW-UHFFFAOYSA-N Y
(verify)
Lansoprazole , sold under the brand name Prevacid among others, is a medication which reduces stomach acid .[4] proton pump inhibitor (PPI), used to treat peptic ulcer disease , gastroesophageal reflux disease , and Zollinger–Ellison syndrome .[5] [6] by mouth .[4] [4]
Common side effects include constipation , abdominal pain , and nausea .[4] [3] osteoporosis , low blood magnesium , Clostridium difficile infectionpneumonia .[4] [3] pregnancy and breastfeeding is of unclear safety.[1] H + /K+ -ATPaseparietal cells of the stomach.[4]
Lansoprazole was patented in 1984 and came into medical use in 1992.[7] generic medication .[5] million prescriptions.[8] [9]
Medical uses
[ edit ]
Lansoprazole is used for treatment of:[3]
There is no good evidence that it works better than other PPIs.[6]
Side effects
[ edit ]
Side effects of PPIs in general[11] [12] [3]
Common: diarrhea, abdominal pain[13]
Infrequent: dry mouth , insomnia , drowsiness , blurred vision , rash , pruritus
Rarely and very rarely: taste disturbance, liver dysfunction, peripheral oedema , hypersensitivity reactions (including bronchospasm , urinary, angioedema , anaphylaxis ), photosensitivity , fever , sweating , depression , interstitial nephritis , blood disorders (including leukopenia , leukocytosis , pancytopenia , thrombocytopenia ), arthralgia , myalgia , skin reactions[14] erythroderma ,[15] Stevens–Johnson syndrome , toxic epidermal necrolysis , bullous eruption )
PPIs may be associated with a greater risk of hip fractures and Clostridium difficile diarrhea .[3] : 22
Interactions
[ edit ]
Lansoprazole interacts with several other drugs, either due to its own nature or as a PPI.[16]
Lansoprazole possibly interacts with, among other drugs:
Chemistry
[ edit ]
It is a racemic 1:1 mixture of the enantiomers dexlansoprazole and levolansoprazole.[18] enantiomeric shift h ) is not proportional to the duration of the drug's effects to the person (i.e. gastric acid suppression).[19]
History
[ edit ]
Lansoprazole was originally synthesized at Takeda and was given the development name AG 1749.[20] [21] [22]
Society and culture
[ edit ] Prevacid 30 mg
Patents
[ edit ]
Patent protection of the lansoprazole molecule expired on 10 November 2009,[23] [24] generic formulations became available under many brand names in many countries.[25] formulations may not be available in generic form.[26]
Availability
[ edit ]
Since 2009, lansoprazole has been available over the counter (OTC) in the U.S. as Prevacid 24HR[27] [28] [29] Pfizer as Zoton.[30]
Research
[ edit ]
In vitro the pathogenic form of tau protein .[31] [update] PET imaging agents for diagnosing tauopathies including Alzheimer's disease .[31]
References
[ edit ]
^ a b c d e f "Lansoprazole capsule, delayed release pellets" . DailyMed . U.S. National Library of Medicine. 11 October 2016. Retrieved 31 December 2019 .
^ a b c d e f "Lansoprazole Monograph for Professionals" . Drugs.com . American Society of Health-System Pharmacists. Retrieved 3 March 2019 .
^ a b British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 79–80. ISBN 9780857113382
^ a b "Comparative effectiveness of proton pump inhibitors" . Therapeutics Initiative . Dept of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia. 28 June 2016. Retrieved 14 July 2016 .
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery ISBN 9783527607495
^ "The Top 300 of 2021" . ClinCalc . Archived from the original on 15 January 2024. Retrieved 14 January 2024 .
^ "Lansoprazole - Drug Usage Statistics" . ClinCalc . Retrieved 14 January 2024 .
^ Hirschowitz BI, Mohnen J, Shaw S (August 1996). "Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome". Alimentary Pharmacology & Therapeutics . 10 4 ): 507–522. doi :10.1046/j.1365-2036.1996.10152000.x . PMID 8853754 . S2CID 10668517 .
^ "1.3.5 Proton pump inhibitors" . British National Formulary . Archived from the original . Retrieved 1 February 2012 .
^ "Lansoprazole" . British National Formulary . Archived from the original . Retrieved 1 February 2012 .
^ "Prevacid (Lansoprazole) Drug Information: Side Effects and Drug Interactions - Prescribing Information" . RxList . Retrieved 9 February 2016 .
^ Salloum A, Nasr D, Maalouf D (April 2021). "Dermatologic adverse reactions to proton-pump inhibitors: A synthetized review". Journal of Cosmetic Dermatology . 20 4 ): 1073–1079. doi :10.1111/jocd.13763 . PMID 33031621 . S2CID 222236157 .
^ Sterry W, Assaf C (2007). "Erythroderma". In Bolognia JL (ed.). Dermatology . St. Louis: Mosby. p. 154. ISBN 978-1-4160-2999-1
^ "Lansoprazole interactions" . British National Formulary . Archived from the original . Retrieved 1 February 2012 .
^ Piscitelli SC, Goss TF, Wilton JH, D'Andrea DT, Goldstein H, Schentag JJ (September 1991). "Effects of ranitidine and sucralfate on ketoconazole bioavailability" . Antimicrobial Agents and Chemotherapy . 35 9 ): 1765–1771. doi :10.1128/aac.35.9.1765 . PMC 245265 PMID 1952845 .
^ "Pharmacy Benefit Update" . Archived from the original on 14 July 2014. Retrieved 2 July 2014 .
^ "Prevacid Pharmacology, Pharmacokinetics, Studies, Metabolism" . RxList.com. 2007. Archived from the original on 16 August 2000. Retrieved 14 April 2007 .
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery ISBN 9783527607495
^ Chorghade MS (2006). Drug Discovery and Development, Volume 1: Drug Discovery ISBN 9780471780090
^ "Lansoprazole" . Mosby's Drug Consult . Archived from the original on 8 February 2009.
^ "Prevacid Drug Profile" . Drugpatentwatch.com. Retrieved 30 April 2020 .
^ Witkowski W (7 November 2008). "Teva to release Prevacid version when patent expires" . Market Watch . Dow Jones.
^ "International availability of lansoprazole" . Drugs.com . Retrieved 3 February 2015 .
^ "Generic lansoprazole" . Drugs.com . Retrieved 20 November 2023 .
^ "Prevacid 24 HR- lansoprazole capsule, delayed release" . DailyMed . U.S. National Library of Medicine. 7 August 2019. Retrieved 31 December 2019 .
^ "Prevacid 24 HR- lansoprazole capsule, delayed release" . DailyMed . U.S. National Library of Medicine. 11 December 2019. Retrieved 31 December 2019 .
^ "Lansoprazole 24 HR- lansoprazole capsule, delayed release" . DailyMed . U.S. National Library of Medicine. 21 December 2017. Retrieved 31 December 2019 .
^ "Zoton FasTabs" . NPS MedicineWise . 2 September 2019. Retrieved 24 April 2022 .
^ a b Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC (January 2015). "Tau imaging: early progress and future directions". The Lancet. Neurology . 14 1 ): 114–124. doi :10.1016/s1474-4422(14 )70252-2 . PMID 25496902 . S2CID 10502833 .
R e t r i e v e d f r o m " https://en.wikipedia.org/w/index.php?title=Lansoprazole&oldid=1212582961 " C a t e g o r i e s : ● B e n z i m i d a z o l e s ● D r u g s d e v e l o p e d b y G S K p l c ● D r u g s d e v e l o p e d b y N o v a r t i s ● O r g a n o f l u o r i d e s ● P h e n o l e t h e r s ● P r o t o n - p u m p i n h i b i t o r s ● P y r i d i n e s ● S a n o f i ● S u l f o x i d e s ● D r u g s d e v e l o p e d b y A b b V i e ● D r u g s d e v e l o p e d b y T a k e d a P h a r m a c e u t i c a l C o m p a n y ● T r i f l u o r o m e t h y l c o m p o u n d s H i d d e n c a t e g o r i e s : ● A r t i c l e s w i t h s h o r t d e s c r i p t i o n ● S h o r t d e s c r i p t i o n i s d i f f e r e n t f r o m W i k i d a t a ● U s e d m y d a t e s f r o m M a r c h 2 0 2 4 ● D r u g s w i t h n o n - s t a n d a r d l e g a l s t a t u s ● E C H A I n f o C a r d I D f r o m W i k i d a t a ● D r u g b o x e s w h i c h c o n t a i n c h a n g e s t o w a t c h e d f i e l d s ● A r t i c l e s c o n t a i n i n g p o t e n t i a l l y d a t e d s t a t e m e n t s f r o m 2 0 1 5 ● A l l a r t i c l e s c o n t a i n i n g p o t e n t i a l l y d a t e d s t a t e m e n t s ● W i k i p e d i a m e d i c i n e a r t i c l e s r e a d y t o t r a n s l a t e
● T h i s p a g e w a s l a s t e d i t e d o n 8 M a r c h 2 0 2 4 , a t 1 6 : 1 3 ( U T C ) . ● T e x t i s a v a i l a b l e u n d e r t h e C r e a t i v e C o m m o n s A t t r i b u t i o n - S h a r e A l i k e L i c e n s e 4 . 0 ;
a d d i t i o n a l t e r m s m a y a p p l y . B y u s i n g t h i s s i t e , y o u a g r e e t o t h e T e r m s o f U s e a n d P r i v a c y P o l i c y . W i k i p e d i a ® i s a r e g i s t e r e d t r a d e m a r k o f t h e W i k i m e d i a F o u n d a t i o n , I n c . , a n o n - p r o f i t o r g a n i z a t i o n . ● P r i v a c y p o l i c y ● A b o u t W i k i p e d i a ● D i s c l a i m e r s ● C o n t a c t W i k i p e d i a ● C o d e o f C o n d u c t ● D e v e l o p e r s ● S t a t i s t i c s ● C o o k i e s t a t e m e n t ● M o b i l e v i e w
